Eiger BioPharmaceuticals, Inc. (EIGR)
(Delayed Data from NSDQ)
$10.50 USD
-0.22 (-2.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Eiger BioPharmaceuticals, Inc. [EIGR]
Reports for Purchase
Showing records 1 - 20 ( 112 total )
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - Dropping Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Zokinvy U.S. Launch Picking Up Pace Ahead of Potential EU Approval by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1: Zokinvy- Launch Underway; Pipeline Advancing into Multiple Phase 3s
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY20 Financials & Pipeline ProgressQ4/FY20 Financials & Pipeline Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2021 Plans: Focus on Zokinvy- Launch and HDV Clinical Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Zokinvy- Approval; AASLD Debriefing, Lambda MonoTx Missing Piece to HDV Mosaic
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
48 Week Phase 2 LIFT Results Bring HDV Program into Sharper Focus; Q3 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Lambda/COVID Active Against High Viral Load; Next, 48wk HDV Combo Data at AASLD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
More Shots on Goal for Lambda/COVID-19; Next, 48wk HDV Combo Data at AASLD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HDV Phase 2 Results Give LMD/LNF Combo a LIFT Heading into AASLD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L